8-K: Cytek Biosciences Reports Mixed Q4/FY25 Results, Guides 2026

Cytek Biosciences reported an 8% increase in Q4 2025 revenue to $62.1 million, its highest quarterly revenue, but full-year revenue grew only 1% to $201.5 million, alongside significant declines in GAAP gross profit and Adjusted EBITDA.

Summary

• Q4 2025 total revenue was $62.1 million, an 8% increase year-over-year, marking the highest quarterly revenue historically for Cytek.
• Full year 2025 total revenue was $201.5 million, a 1% increase compared to full year 2024.
• Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of total revenue.
• Adjusted EBITDA for the full year ended December 31, 2025, was $5.0 million, a significant decrease from $22.4 million for the full year 2024.
• The company expanded to a total installed base of 3,664 Cytek instruments, with 630 total instruments placed during 2025.
• Unit placements of Cytek's Aurora CS system grew 22% in 2025 over the prior year.
• Launched the Cytek Aurora Evo system, a new full spectrum flow cytometer offering faster sample throughput, automated instrument startup and shutdown, enhanced resolution for small particle detection, and data harmonization.
• Launched the Cytek Muse Micro cell analyzer, which was awarded the 2025 Biotech Breakthrough Award for Drug Discovery Solution of the Year.
• Net loss in the fourth quarter of 2025 was $44.1 million, compared to a net income of $9.6 million in the fourth quarter of 2024, primarily due to a non-cash valuation allowance against deferred tax assets of $38.1 million.
• Net loss for the full year 2025 was $66.5 million, compared to a net loss of $6.0 million for the full year 2024.
• Cash and marketable securities totaled $261.5 million as of December 31, 2025, a decrease of $16.4 million from $277.9 million as of December 31, 2024, partly due to the repurchase of approximately 3.3 million shares for $15.1 million during 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to the significant decline in profitability metrics (gross profit, Adjusted EBITDA, net income/loss) and only modest full-year revenue growth, despite some positive Q4 momentum and new product launches. The large non-cash tax valuation allowance further highlights underlying financial challenges.

Positives

• Q4 2025 total revenue increased 8% to $62.1 million, marking the highest quarterly revenue achieved historically.
• Total recurring revenue (service and reagent) grew 21% in 2025 compared to 2024, now representing 34% of total revenue, indicating a more stable revenue base.
• Expanded the total installed base to 3,664 Cytek instruments, with 630 instruments placed during 2025.
• Unit placements of Cytek's Aurora CS system grew 22% in 2025 over the prior year.
• Successfully launched two new innovative products: the Cytek Aurora Evo system and the Cytek Muse Micro cell analyzer, with the latter receiving the 2025 Biotech Breakthrough Award for Drug Discovery Solution of the Year.
• Experienced strong momentum in FSP instrument sales across all major markets worldwide in Q4 2025.
• Saw improving instrument demand in both the US and EMEA during Q4 2025.

Negatives

• Full year 2025 total revenue growth was only 1% ($201.5 million compared to $200.453 million in 2024).
• GAAP gross profit decreased by 6% for the full year 2025 to $104.5 million from $111.1 million in 2024.
• GAAP gross profit margin declined to 52% for full year 2025 from 55% in 2024.
• Adjusted EBITDA for full year 2025 significantly declined to $5.0 million from $22.4 million in 2024.
• Net loss for Q4 2025 was $44.1 million, a substantial shift from a net income of $9.6 million in Q4 2024, primarily due to a $38.1 million non-cash valuation allowance against deferred tax assets.
• Net loss for full year 2025 widened to $66.5 million from $6.0 million in 2024.
• Operating expenses increased 10% for the full year 2025 to $144.8 million, driven by a 36.7% increase in general and administrative expenses (due to higher patent litigation, compensation, sales and use tax, and software expenses).
• Cash and marketable securities decreased by $16.4 million for the full year 2025.
• Full year 2025 revenue on a non-GAAP constant currency basis declined by 1.1% to $198.2 million.

Risks

• Global geopolitical, economic, and market conditions could impact operations and financial performance.
• Ability to manage the impacts of recent and future export controls, licensing requirements, tariffs, and NIH funding policies on the business.
• Ability to evaluate prospects for future viability and predict future performance accurately.
• Ability to accurately forecast customer demand and adoption of products.
• Ability to recognize the anticipated benefits of collaborations.
• Dependence on certain sole and single-source suppliers poses supply chain risks.
• Competition in the cell analysis market could affect market share and pricing.
• Market acceptance of current and potential products is crucial for revenue growth.
• Ability to manage the growth and complexity of the organization, maintain relationships with customers and suppliers, and hire and retain key employees.
• Ability to manufacture products in high-quality commercial quantities successfully and consistently to meet demand.
• Ability to increase penetration in existing markets and expand into adjacent markets.
• Ability to secure additional distributors or maintain good relationships with existing distributors.
• Ability to successfully develop and introduce new products.
• Ability to maintain, protect, and enhance intellectual property.
• Ability to continue to stay in compliance with material contractual obligations, applicable laws, and regulations.
• Foreign currency exchange impacts could negatively affect financial results.

Future Outlook

Cytek Biosciences anticipates full year 2026 revenue to be in the range of $205 million to $212 million, representing a growth of 2% to 5% over full year 2025, assuming stable foreign currency exchange rates and 2025 US tariff policy. The company's priorities for 2026 include growing high-margin recurring revenue lines, accelerating instrument platform adoption, advancing new product pipelines, and delivering profitable, durable growth in the large cell analysis market.

Management Comments

• "We were pleased by our fourth quarter revenue growth, which marked a clear acceleration versus the prior year and a continuation of the positive trends we saw earlier in 2025."
• "Our revenue performance in the quarter was driven by strong momentum in FSP instrument sales in all major markets worldwide alongside sustained growth in our recurring revenue streams."
• "We were especially encouraged to see improving instrument demand in both the US and EMEA."
• "This broad-based execution positions us well for 2026, where our priorities will continue to focus on the growth of our high-margin recurring revenue lines, accelerating the adoption of our instrument platforms, advancing a pipeline of innovative new products, and delivering profitable, durable growth in the large cell analysis market."

Industry Context

StockSavvy.ai notes that Cytek Biosciences operates in the highly competitive and innovation-driven cell analysis market, which is experiencing increasing demand for advanced research tools. The company's focus on full spectrum profiling (FSP) technology and the launch of new systems like the Aurora Evo and Muse Micro indicate a strategy to differentiate through technological superiority and accessibility. The growth in recurring revenue streams aligns with a broader industry trend towards subscription-based models and consumables, providing more stable revenue. However, the significant decline in Adjusted EBITDA and widening net loss, despite revenue growth, suggests challenges in cost management or pricing power within this competitive landscape.

Legal Proceedings

• Increased general and administrative expenses for Q4 and full year 2025 were partly due to higher litigation-related expenses and patent litigation expenses.
• A non-recurring benefit of $2.6 million in Q4 2024 related to a change in estimate of an adjustment to a license and royalty settlement liability was noted, indicating past legal settlements.

Stakeholder Impact

• Shareholders: Negative impact due to significant net losses, declining Adjusted EBITDA, and only modest revenue growth, potentially affecting stock valuation. Share repurchases in 2025 might offer some support but are overshadowed by financial performance.
• Employees: Increased headcount mentioned as a factor in higher general and administrative expenses, suggesting continued investment in human capital despite overall financial challenges.
• Customers: Benefit from new product launches (Aurora Evo, Muse Micro) offering improved capabilities and accessibility in cell analysis.
• Suppliers: Continued operations and product development imply ongoing relationships, but potential cost pressures could impact supplier negotiations.
• Creditors: The decline in profitability and increase in net loss could raise concerns, though cash and marketable securities remain substantial at $261.5 million.

Next Steps

• Host a conference call on February 26, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss financial results.
• File the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC on or about the date of the press release.
• Continue to focus on growth of high-margin recurring revenue lines.
• Accelerate adoption of instrument platforms.
• Advance a pipeline of innovative new products.
• Deliver profitable, durable growth in the cell analysis market.

Key Dates

Recommendation

The filing reveals a significant deterioration in profitability, with a substantial increase in net loss and a sharp decline in Adjusted EBITDA for the full year 2025, despite a slight revenue increase. The non-cash valuation allowance against deferred tax assets further underscores financial uncertainty. While Q4 revenue showed some acceleration and new products were launched, the overall financial health and outlook for 2-5% growth in 2026 do not justify a positive investment stance given the current performance trends and increased operating costs, particularly litigation expenses. Investors should consider selling to mitigate further downside risk.

Keywords

Cell analysis, Flow cytometry, Full Spectrum Profiling (FSP), Biotechnology, Life sciences, Cytek Aurora, Cytek Muse Micro, Financial results, CTKB, SEC filing